Download our official Acadia brand media assets to enrich your publications and presentations. Please use these assets in accordance with our brand guidelines to ensure consistency and proper representation.
Therapeutic Area Fact Sheets
About Acadia
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, addressing critical unmet needs. Building on this foundation of excellence, we are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs.
